{"id":"NCT01455181","sponsor":"Shire","briefTitle":"A Study to Investigate the Safety and Tolerability of NPSP558, for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study in Hungary","officialTitle":"A 6-Month Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-08-19","primaryCompletion":"2012-04-26","completion":"2012-04-26","firstPosted":"2011-10-19","resultsPosted":"2015-03-06","lastUpdate":"2021-06-11"},"enrollment":24,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hypoparathyroidism"],"interventions":[{"type":"DRUG","name":"NPSP558","otherNames":["REPEAT"]}],"arms":[{"label":"NPSP558","type":"EXPERIMENTAL"}],"summary":"This study is designed to evaluate the effect of 6-months of treatment with NPSP558 in reducing requirements for supplemental oral calcium and active vitamin D, while maintaining stable total serum calcium levels in adult subjects with hypoparathyroidism.","primaryOutcome":{"measure":"Percentage of Subjects Who Achieved the Primary Triple Endpoint at Week 24, Based on Investigator Prescribed Data.","timeFrame":"24 Weeks","effectByArm":[{"arm":"NPSP558","deltaMin":75,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":3,"countries":["Hungary"]},"refs":{"pmids":["26684150"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":24},"commonTop":["Hypoaesthesia","Muscle spasms","Vitamin D decreased","Hypercalcaemia","Headache"]}}